Tetanus is a frequently fatal disease caused by the bacterium Clostridium tetani. The disease is characterized by intense, painful muscle contractions, sometimes strong enough to break even the
Excess drinking on New Year's Eve can lead to a painful morning after, with no sure-fire cure available. But helpful strategies for treating a hangover do exist. Hangover Symptoms headache nausea dizziness
The U.S. Food and Drug Administration (FDA) approved Xepi (ozenoxacin) Cream, 1%, a new chemical entity for the treatment of impetigo in patients two months of age and older when applied topically twice daily for 5 days. In the U.S., impetigo is estimated to account for approxima
The U.S. Food and Drug Administration is investigating serious adverse events involving Flavocoxid (Limbrel), a product in capsule form currently being marketed as a medical food to manage the metabolic processes associated with osteoarthritis.
While a range of adverse events ha
Juluca is a fixed-dose tablet containing two previously approved drugs (dolutegravir and rilpivirine)
The U.S. Food and Drug Administration today approved first two drug HIV regimen (Juluca), the first complete treatment regimen containing only
15 November 2017:
This year's theme: Seek advice from a qualified healthcare professional before taking antibiotics.
Antibiotics are a precious resource, so it is important to get the right advice before taking them.
This not only ensures you and your family get the best
Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age.
Two different DNA-based treatment : an
Strategic Advisory Group of Experts on Immunization and WHO makes new recommendations for vaccines to battle typhoid fever and rabies: October 2017
Polio eradication initiative:
To date, 4 countries have decided to move to a fractional inactivated poliovirus
The US Food and Drug Administration (FDA) has approved golimumab (Simponi Aria, Janssen Biotech) for adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).
Golimumab, an inhibitor of tumor necrosis factor (TNF)-α, is already approved for treatment
US Food and Drug Administration (FDA) advisory panel voted nearly unanimously in favor of approval for Novo Nordisk's once-weekly injectable semaglutide, despite a signal for increased retinopathy. If approved, it would be the seventh GLP-1 receptor agonist on the US market and